Astellas Pharma News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

31.10.23	Ausblick: Astellas Pharma gewährt Anlegern Blick in die Bücher (finanzen.net)
22.10.23	Groundbreaking EV-302 Trial Significantly Extends Overall Survival and Progression-Free Survival in Patients Treated with PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) in First-L... (PR Newswire)
17.10.23	Erste Schätzungen: Astellas Pharma mit Zahlen zum abgelaufenen Quartal (finanzen.net)
16.10.23	Astellas to Share New Data Across Hard-to-Treat Cancers During ESMO Congress 2023 (PR Newswire)
13.10.23	Astellas' Veoza Receives Positive CHMP Opinion For Treatment Of VMS Associated With Menopause (RTTNews)
13.10.23	Astellas Receives Positive CHMP Opinion for VEOZA™ (fezolinetant) (PR Newswire)
11.10.23	Astellas Pharma, BioLabs And Mitsui Fudosan Collaborate To Enhance Life Science Ecosystems In Japan (RTTNews)
11.10.23	Astellas, BioLabs and Mitsui Fudosan Announce a Collaboration to Enhance the Life Science Ecosystems in Tsukuba and Kashiwa-no-ha, Japan (PR Newswire)
28.09.23	MÄRKTE ASIEN/Uneinheitlich - Tokio und Hongkong sehr schwach (Dow Jones)
28.09.23	MÄRKTE ASIEN/Tokio und Hongkong schwach - Evergrande wieder ausgesetzt (Dow Jones)
22.09.23	Merck Says Phase 3 KEYNOTE-A39/EV-302 Trial Meets Dual Primary Endpoints (RTTNews)
22.09.23	Seagen, Astellas Pharma Report Positive Topline Results From EV-302 Trial (RTTNews)
22.09.23	PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) Significantly Improve Overall Survival and Progression-Free Survival in Patients With Previously Untreated Advanced Bladder Cancer i... (PR Newswire)
20.09.23	Two-time Emmy® Award-Winning Actor, Eric Stonestreet, Partners with Iveric Bio to Raise Awareness of Geographic Atrophy (GA) (PR Newswire)
19.09.23	Astellas Pharma Announces Positive Results From Phase 3 Trial Of Izervay In Geographic Atrophy (RTTNews)
19.09.23	Iveric Bio Announces Positive 24-Month Topline Results from Phase 3 Study of IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic Atrophy (PR Newswire)
19.09.23	Astellas Venture Management and MBC BioLabs Announce the 5th Annual Astellas Future Innovator Prize (PR Newswire)
18.09.23	Astellas Highlights VEOZAH™ (fezolinetant) Data at the 2023 Annual Meeting of The Menopause Society (PR Newswire)
14.09.23	Astellas To Invest More Than EUR 330 Mln In State-of-the-Art Facility In Tralee, Co. Kerry, Ireland (RTTNews)
14.09.23	Astellas to Invest more than €330 Million in a New State-of-the-Art Facility in Tralee, Co. Kerry. Ireland (PR Newswire)
13.09.23	EMA Validates Type II Variation For Astellas' XTANDI For Treatment Of Prostate Cancer (RTTNews)
13.09.23	European Medicines Agency Validates Type II Variation for Astellas' XTANDI® (enzalutamide) for Treatment of Non-Metastatic Hormone-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence (PR Newswire)
23.08.23	Pfizer, Astellas' XTANDI Gets Priority Review In Non-metastatic Castration-sensitive Prostate Cancer (RTTNews)
23.08.23	FDA Grants Priority Review for XTANDI® in Non-Metastatic Castration-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence (PR Newswire)
18.08.23	Astellas : EMA Accepts Iveric Bio's MAA For Avacincaptad Pegol For Geographic Atrophy (RTTNews)
18.08.23	European Medicines Agency Accepts Iveric Bio's Marketing Authorization Application for Avacincaptad Pegol for Geographic Atrophy (PR Newswire)
10.08.23	Astellas to Open New Life Sciences Facility in DivcoWest's Cambridge Crossing Neighborhood (PR Newswire)
07.08.23	Astellas, Poseida Announce Investment To Support Poseida's Commitment To Cancer Cell Therapy (RTTNews)
07.08.23	Astellas and Poseida Therapeutics Announce Strategic Investment to Support Poseida's Commitment to Redefining Cancer Cell Therapy (PR Newswire)
07.08.23	MÄRKTE ASIEN/Negative US-Vorgaben lasten auf der Stimmung (Dow Jones)
05.08.23	Iveric Bio Receives U.S. FDA Approval for IZERVAY™ (avacincaptad pegol intravitreal solution), a New Treatment for Geographic Atrophy (PR Newswire)
01.08.23	China's National Medical Products Administration Accepts Astellas' Biologics License Application for Zolbetuximab (PR Newswire)
31.07.23	Biotech Stocks Facing FDA Decision In August 2023 (RTTNews)
31.07.23	Ausblick: Astellas Pharma gewährt Anlegern Blick in die Bücher (finanzen.net)
18.07.23	Astellas and Eko Health Announce Agreement to Incorporate Next Generation Eko CORE 500™ Digital Stethoscope into Z1608, an Innovative Solution Under Development for Heart Failure Patients Built on... (PR Newswire)
17.07.23	Erste Schätzungen: Astellas Pharma präsentiert das Zahlenwerk zum abgelaufenen Jahresviertel (finanzen.net)
14.07.23	EMA Accepts Astellas' Marketing Authorization Application For Zolbetuximab (RTTNews)
14.07.23	European Medicines Agency Accepts Astellas' Marketing Authorization Application for Zolbetuximab (PR Newswire)
12.07.23	Astellas Completes Acquisition of Iveric Bio (PR Newswire)
11.07.23	Astellas and 4D Molecular Therapeutics (4DMT) Enter into License Agreement to Use 4DMT's Proprietary Intravitreal R100 Vector for Rare Ophthalmic Targets (PR Newswire)
06.07.23	Astellas Announces U.S. FDA Grants Priority Review for Zolbetuximab Biologics License Application (PR Newswire)
29.06.23	Astellas Establishes Open Innovation Hub for Tumor Microenvironment Research with Cutting-Edge Spatial Biology, in Mitsui Fudosan's "MITSUI LINK-Lab KASHIWA-NO-HA 1" (PR Newswire)
28.06.23	Astellas :Phase 3 Trial Of Fezolinetant Shows Positive Results For Treatment Of VMS Due To Menopause (RTTNews)
28.06.23	Phase 3b Trial of Fezolinetant Shows Positive Topline Results for Treatment of VMS Due to Menopause (PR Newswire)
15.06.23	Astellas, Cullgen Team Up To Discover Innovative Targeted Protein Degraders (RTTNews)
15.06.23	Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders (PR Newswire)
09.06.23	Gilteritinib as Maintenance Therapy Demonstrated Benefit in Subgroups of FLT3-ITD Acute Myeloid Leukemia Patients (PR Newswire)
09.06.23	Astellas Submits NDA For Zolbetuximab In Japan For Advanced Gastric, Gastroesophageal Cancers (RTTNews)
09.06.23	Astellas Submits New Drug Application for Zolbetuximab in Japan (PR Newswire)
08.06.23	Astellas, Kate Therapeutics Ink License Agreement For Gene Therapy Candidate KT430 (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

CieFinRichemont	121.65	2.61 %	K V
UBS Group	28.75	1.59 %	K V
Part Grp Hldg	1’276.50	1.03 %	K V
Sika	233.50	0.91 %	K V
ABB	50.56	0.80 %	K V
Swisscom	508.00	-0.29 %	K V
Zurich Insur Gr	551.20	-0.33 %	K V
Givaudan	3’916.00	-0.43 %	K V
Roche Hldg G	252.70	-0.63 %	K V
Novartis	92.41	-1.36 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Astellas Pharma Inc Unsponsored American Deposit Receipt Repr 1-4 Sh

Aktien Top/Flop

Meistgelesene Nachrichten